Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 4, 1999, Pages 523-528

  Schmid, Christopher R ^a   Sluka, James P ^a   Duke, Kristen M ^a   Glasebrook, Andrew W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE;

ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CARBON; CELL DIVISION; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; OXYGEN; PIPERIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

THIA;

EID: 0033593919     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00050-5     Document Type: Article

References (32)

1. 1. (a) Jones, C. D.; Jevikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. J. Med. Chem. 1984, 27, 1057.
2. (b) Delmas, P. E.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A-C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. N. Engl. J. Med. 1997, 337 (23), 1641.
3. (c) Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. J. Bone Mineral Res. 1996, 11, 835.
4. 2. (a) Grese, T. A.; Dodge, J. A. Curr. Pharm. Des. 1998, 4, 71.
5. (b) Bryant, H. U.; Dere, W. H. Proc. Soc. Exp. Biol. Med. 1998, 217, 45.
6. (c) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Proc. Nat. Acad. Sci. U.S.A. 1997, 94, 14105.
7. (d) Grese, T. A.; Dodge, J. A. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: New York, 1996; Vol. 31, pp 181-190.
8. (e) Kauffman, R. F.; Bryant, H. U. Drug News Perspect. 1995, 8, 531.
9. (f) Evans, G. I.; Turner, R. T. Bone 1995, 17, 1818.
10. 3. (a) Pennisi, E. Science 1996, 273, 1171.
11. (b) Fink, G.; Sunmer, B. E. H. Nature 1996, 383, 306.
12. (c) Dempster, D. W.; Lindsay, R. Lancet, 1993, 341, 797.
13. (d) Lindsay, R. Lancet 1993, 341, 801.
14. (e) Riggs, B. C.; Melton, L. J. New Engl. J. Med. 1992, 327, 620.
15. 4. (a) Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1998, 41, 1272.
16. (b) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. J. Med. Chem. 1997, 40, 1407.
17. (c) Grese, T. A.; Cho, S.; Finley, D. A.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W. III; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. J. Med. Chem. 1997, 40, 146.
18. (d) Martin, M. J.; Grese, T. A.; Glasebrook, A. L.; Matsumoto, K.; Pennington, L. D.; Phillips, D. L.; Short, L. L. Bioorg. Med. Chem. Lett. 1997, 7, 887.
19. (e) Grese, T. A.; Cho, S.; Bryant, J. U.; Cole, H. W.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L. Bioorg. Med. Chem. Lett. 1996, 6, 201.
20. (f) Cameron, K. O.; Da Silva-Jardine, P.; Larson, E. R.; Hauske, J. R.; Rosati, R. L. PCT Int'l Appl. WO9510513; Chem. Abstr. 1995, 123, 143630.
21. (f) Cameron, K. O.; Da Silva-Jardine, P.; Larson, E. R.; Hauske, J. R.; Rosati, R. L. PCT Int'l Appl. WO9510513; Chem. Abstr. 1995, 123, 143630.
22. 5. Marron, K. S.; Schmid, C. R.; Sluka, J. P. Eur. Pat. Appl. EP838464 A1 980429; Chem. Abstr. 1998, 128, 308395.
23. 5. Marron, K. S.; Schmid, C. R.; Sluka, J. P. Eur. Pat. Appl. EP838464 A1 980429; Chem. Abstr. 1998, 128, 308395.
24. 6. Details of this work will appear separately: Schmid, C. R.; Sluka, J. P.; Duke, K. M. Tetrahedron Lett. 1999, 40, 675. Accepted for publication.
25. 7. Smith, W. J. III; Sawyer, J. S. Tetrahedron Lett. 1996, 37, 299.
26. 8. Shiniriki, N.; Nambara, T. Chem. Pharm. Bull. (Tokyo) 1963, 11, 178.
27. 9. (a) Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. J. Bone Miner. Res. 1993, 8, S268 (suppl 1).
28. (b) Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graff, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Cancer Res. 1988, 48, 6764.
29. 10. RBA values represent an average of two or more determinations and are accurate to ±10%. Antiproliferative values represent an average of three or more determinations and are accurate to ±10%.
30. 11. (a) Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L; Greene, G. L.; Gustafsson, J-A.; Carlquist, M. Nature 1997, 389, 753.
31. (b) Entry 1ERR from the Brookhaven Protein Data Bank at http://www.pdb.bnl.gov/.
32. 12. Molecular mechanics simulations were carried out using the cvff forcefield with Insight II version 97.2 from Molecular Simulations Inc., San Diego, CA.